Methods: Forty patients with ACCs, including 12 pairs of primary and metastatic ACCs, were evaluated for the immunohistochemical expression of TTF-1 (clone SPT24). In addition, 10 metastatic ACCs to the lung were tested on napsin A and a different TTF-1 antibody (clone 8G7G3) for further evaluation.
Results:
No primary ACCs showed TTF-1 immunoreactivity (clone SPT24). TTF-1 was positive in five (41.7%) of 12 metastatic ACCs; all five cases were found only in the lung and comprised five (50.0%) of 10 cases. In all positive cases, staining was focal and detected only in the cribriform histologic subtype. Staining patterns using both antibodies (both SPT24 and 8G7G3) were very similar, and TTF-1-positive tumor cells were also positive for napsin A. Extrapulmonary ACCs were all negative for TTF-1 regardless of origination and metastasis.
Conclusions: TTF-1-and napsin A-positive ACCs in the lung should not be considered primary ACCs because TTF-1 and napsin A can be expressed in metastatic ACCs of the lung.
Primary adenoid cystic carcinoma (ACC) of the lung is a very rare disease and probably accounts for 0.04% to 0.2% of all primary lung tumors. 1 ACC has a propensity for late and multiple distant metastases, with the lung being the most commonly involved organ. 2 Differential diagnoses of primary ACCs in the lung from metastatic carcinomas to the lung are sometimes challenging. Unfortunately, there is no reliable biomarker in differential diagnoses. Clinical information is of paramount importance for discriminating.
Thyroid transcription factor 1 (TTF-1) is a DNA-binding protein that controls the expression of thyroid, lung, and rostral brain-specific genes and plays a critical role in the embryogenesis of these organs. It is essential for the expression of several proteins, including thyroglobulin, thyroperoxidase, surfactant protein A, and Clara cell secretory protein. 3 TTF-1 is expressed in both normal and neoplastic lung and thyroid tissues. Therefore, TTF-1 was thought to be a reliable marker of origination from either site. 4 Practically, TTF-1 is a very useful marker for primary adenocarcinoma of the lung. 3, 5 For this purpose, immunostaining for TTF-1 is used to diagnose a lung primary lesion. However, metastatic carcinomas to the lung from the endometrium, endocervix, ovary, and colon have been reported positive for TTF-1. [6] [7] [8] [9] [10] [11] Although only one case report has shown TTF-1 immunoreactivity in an ACC originating in the lung, 12 the prevalence of TTF-1 expression in ACCs has not been studied in large numbers. Napsin A was originally described as a functional aspartic protease that is predominantly expressed in the epithelial cells of lung and kidney and, to a much lesser extent, the spleen and leukocytes. 13 Napsin A immunohistochemistry has been a useful diagnostic adjunct for classifying lung and renal carcinomas. 6, 14, 15 Napsin A is usually considered superior to TTF-1 for distinguishing primary lung adenocarcinoma from other carcinomas. 15 After we incidentally found TTF-1 immunoreactivity in a case of ACC in the lung, we undertook this study to evaluate TTF-1 expression in primary and metastatic ACCs and performed additional immunohistochemical stains on metastatic ACCs in the lung using napsin A and different TTF-1 antibodies.
Materials and Methods

Case Selection
Forty patients diagnosed with ACC in various organs, including salivary glands, between 1998 and 2012 were selected from the pathology database of the Department of Pathology, Ewha Womans University Mok-dong Hospital, Seoul, Korea. Clinical information, including patients' age, sex, and the pathologic features of the ACCs, was reviewed. The primary locations of the ACCs were the major salivary gland (n = 15), nasal cavity (n = 7), oral cavity (n = 6), lung (n = 3), breast (n = 2), ear (n = 2), pharynx (n = 2), skin (n = 2), and uterus (n = 1). Histopathologic features were reviewed from H&E-stained slides. The tumors were subdivided into cribriform, solid, and tubular types. Of the 40 cases, distant metastatic tumors were identified in 12 (30.0%). The metastatic locations were the lung (n = 10), liver (n = 1), and lymph node (n = 1). This study adhered to the principles of the Declaration of Helsinki.
Immunohistochemistry
Paraffin-embedded blocks from 39 primary ACCs and 12 metastatic ACCs were available for immunohistochemistry. In one case (case 3), the primary tumor was not biopsied because the metastatic lung nodule was incidentally found and biopsied first. Immunohistochemical staining for TTF-1, clone SPT24 (Novocastra, Newcastle upon Tyne, England); TTF-1, clone 8G7G3 (DAKO, Carpinteria, CA); and napsin A, clone IP64 (Novocastra) was carried out using a Bond Max Autostainer (Leica Biosystems, Melbourne, Australia). The 4-μm-thick sections from paraffin-embedded blocks were deparaffinized, and endogenous peroxidase was inactivated. Antigen retrieval was performed using the Bond Epitope Retrieval Solution 2 (ER2, Leica Biosystems) at 99°C to 100°C for 20 to 30 minutes. After retrieval, the sections were incubated sequentially with the primary antibody for 15 minutes, the post-primary antibody for 10 minutes, and the polymer for 30 minutes, followed by 3,3′-diaminobenzidine staining (Bond Polymer Refine Detection Kit; Leica Biosystems). The slides were counterstained with hematoxylin and mounted.
Results
Of the 40 patients with ACC, 13 were male and 27 were female. Their mean age at diagnosis was 55.8 years (range, 23-79 years). The clinicopathologic features of patients and tumors are summarized in ❚Table 1❚. Of the 40 cases, 29 (72.5%) were cribriform type, seven (17.5%) were solid type, and four (10.0%) were tubular type. Twelve patients developed distant metastases, with the lung (n = 10) being the most common metastatic site, followed by the liver (n = 1) and lymph node (n = 1).
On immunohistochemical staining, none of the primary ACCs demonstrated TTF-1 immunoreactivity, including three cases of primary ACCs in the lung. Of the 12 metastatic cases, five (41.7%) were immunoreactive for TTF-1 irrespective of TTF-1 clones (SPT24 and 8G7G3). All TTF-1-positive cases were metastatic ACCs to the lung, constituting five (50.0%) of 10 metastatic ACC cases in the lung. All TTF-1-positive metastatic cases were cribriform histologic subtypes, and the nuclear staining of TTF-1 was focal. There was no cytoplasmic staining. The staining patterns of each antibody (SPT24 and 8G7G3) were very similar, and all TTF-1-positive cases also showed focal cytoplasmic napsin A immunoreactivity ❚Image 1❚ and ❚Image 2❚. The immunohistochemical results are summarized in Table 1 and ❚Table 2❚.
Discussion
The purpose of this study was to evaluate the expression of TTF-1 in primary and metastatic ACCs arising in sites including major salivary glands, nasal cavity, oral cavity, and lung. Our focus was comparison of primary and metastatic ACCs of the lung. We incidentally found a case of ACC of the lung showing nuclear TTF-1 immunoreactivity, originally considered a primary ACC arising in the lung. However, a primary tumor was identified in the sublingual gland after systemic workup, and the primary tumor did not have TTF-1 immunoreactivity.
To our knowledge, the prevalence of TTF-1 positivity in ACCs has not been reported. Only one case report found TTF-1 expression in ACC arising in the lung. In the study by Kitada et al, 12 the diagnosis was primary lung cancer because the tumor was positive for TTF-1 and no thyroid lesions were present. However, a salivary gland tumor had been resected 19 years in the past, but pathologic information unfortunately was not available. Considering the results of our study, the possibility of TTF-1-positive metastatic ACC of salivary gland origin should be considered and a diagnosis of primary lung cancer should not be based solely on TTF-1 expression.
One pitfall in evaluating TTF-1 staining of lung tumors is the nonspecific staining of entrapped pneumocytes 
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❚Image 1❚ Example of lung metastatic adenoid cystic carcinoma in a needle biopsy specimen (case 2). Focal nuclear expression of thyroid transcription factor 1 (clone 8G7G3 from DAKO, Carpinteria, CA) (A) and focal cytoplasmic expression of napsin A (B) (x100).
surrounding or within tumors, which can be immunoreactive for TTF-1 and napsin A. In this study, TTF-1-and napsin Apositive cells were identified in the center of metastatic ACCs in the lung, making interpretation very difficult. Usually, in the periphery of tumor nests, TTF-1-and napsin A-positive cells seemed like benign nonneoplastic lung epithelium surrounding tumor nests, but TTF-1-and napsin A-positive cells in the center were considered tumor cells that aberrantly expressed TTF-1 and napsin A. The reason TTF-1 was expressed only in some cases of metastatic ACCs of the lung but not in primary tumors is unknown. However, the question of a possible role of lung microenvironment should be explored. To evaluate the potential microenvironmental role for TTF-1 expression, we retrospectively performed TTF-1 immunostaining on primary tumors of lung metastatic ACCs with aberrant TTF-1 expression. None of the primary ACCs had TTF-1 immunoreactivity. Therefore, a role of lung microenvironment is ❚Image 2❚ Example of lung metastatic adenoid cystic carcinoma in a resection specimen (case 5). Focal nuclear staining of thyroid transcription factor 1 (TTF-1) (clone SPT24 from Novocastra, Newcastle upon Tyne, England) (A, ×40; B, ×200). Focal nuclear staining of TTF-1 (clone 8G7G3 from DAKO, Carpinteria, CA) (C, ×200) and focal cytoplasmic expression of napsin A (D, ×200). a possible mechanism. Another possibility is the difference in the reactivity of antibody clones. Two main commercially available clones of monoclonal antibodies, 8G7G3/1 from DAKO and SPT24 from Novocastra, were present. It has been reported that the antibody of the SPT24 clone is superior for its consistent nuclear positivity and less erratic cytoplasmic staining. 16 Comperat et al 7 showed that the SPT24 clone was much more sensitive than the 8G7G3/1 clone, with a positive rate of 84% vs 65% in cases of primary adenocarcinomas of the lung. The recently commercially available SPT24 anti-TTF-1 monoclonal antibody was used in most cases in which TTF-1 positivity was demonstrated, but reactivity also has been reported with the more commonly used 8G7G3 antibody, although at lower percentages. 17 As Comperat et al suggested, it is possible that TTF-1 may be aberrantly expressed by some genetic alterations. As shown in this study, both TTF-1 clones showed very similar patterns of immunoreactivity. Therefore, the possibility of difference in the reactivity of antibody clones is very low. Napsin A is distributed mainly in type II pneumocytes, alveolar macrophages, renal tubules, and pancreatic exocrine glands and ducts. 14 In this study, a napsin A stain was performed to evaluate the possibility that TTF-1-positive cells may be entrapped pneumocytes. As expected, entrapped pneumocytes surrounding tumor nests were positive for napsin A. However, TTF-1-positive tumor cells in the center were also unexpectedly positive for napsin A. To our knowledge, the aberrant expression of napsin A in ACCs has not been described in the literature.
The present study has several limitations. First, case numbers of metastatic and primary ACCs in the lung are small. Further studies using more cases of primary and metastatic ACCs in the lung are needed. Second, metastasis was usually diagnosed by needle biopsy, which cannot represent the whole tissue. TTF-1 positivity can be underestimated in some cases.
The aberrant expression of TTF-1 and napsin A in metastatic ACCs to the lung is a very unusual finding and has not been described in the literature. Although study samples are small in number, the fact that metastatic ACCs to the lung can express aberrant TTF-1 would help pathologists not to misdiagnose metastatic tumors as primary lung tumors. Additional studies using more cases are mandatory for further evaluation.
In conclusion, even though TTF-1 and napsin A are considered sensitive and specific biomarkers for thyroid and lung neoplasms, they can be expressed in metastatic ACCs of the lung, although TTF-1 is negative in primary tumors. All cases show focal staining. Therefore, TTF-1 expression should be interpreted in the context of the clinical setting, radiologic findings, and pathologic staining pattern.
